Orforglipron

Orforglipron (brand name Foundayo) belongs to the same drug family as semaglutide and tirzepatide — a group called GLP-1 receptor agonists (drugs that copy a natural gut hormone to curb appetite and steady blood sugar). But it has one big difference: it is a small molecule rather than a peptide (a small, chemically built drug instead of a chain of amino acids), so it can be taken as a once-daily pill instead of an injection. In April 2026 the FDA approved it for long-term weight management, making it the first oral small-molecule GLP-1 drug on the market. The older GLP-1 drugs are peptides that the gut digests, so getting this same effect into a convenient daily pill has been a goal for years. Orforglipron is the first to reach that goal with a clean regulatory approval and a large body of Phase 3 (large, late-stage human trial) evidence behind it.

What it is

Orforglipron is an oral GLP-1 receptor agonist that is not a peptide. That distinction matters: it is a small, lab-built molecule rather than a peptide. Peptide GLP-1 drugs (semaglutide, liraglutide, tirzepatide) get broken down by enzymes in the gut, which is why they have to be injected — and why even the oral form of semaglutide has to be taken on an empty stomach with strict water rules. Orforglipron was deliberately built as a small molecule to get around that problem.

Here is how it works in the body. It is described as an allosteric, G-protein–biased partial agonist of the GLP-1 receptor — meaning it attaches to a side spot on the receptor (rather than the hormone’s usual landing site), only partly switches it on, and steers the signal down one particular pathway. In plainer terms, it binds a spot that sits within the cell membrane and favors the Gs/cAMP signal (one internal messaging route) over the β-arrestin signal (another route). What it does from there is the standard GLP-1 effect: it prompts insulin release when blood sugar is high, slows how fast the stomach empties, and dials down appetite in the brain. The way the body handles the drug supports once-daily pills with no food, water, or timing rules. Its half-life (how long it takes the body to clear half a dose) depends on the dose and how long you have been taking it — roughly 25–35 hours after a single dose, rising to roughly 48–68 hours once levels have settled at a steady state.

It started at Chugai Pharmaceutical (development code OWL-833) and was licensed to Eli Lilly in 2018, which carried it forward as LY3502970 and finally as Foundayo.

The claims

The pitch is simple: an oral GLP-1 pill that delivers injection-level weight loss without the injection and without diet restrictions. The things actually worth checking are how much weight people really lose, whether it works for type 2 diabetes, whether it is a peptide (it is not), whether it protects muscle, and where it stands with anti-doping rules. Some posts online also claim that anti-doping authorities have banned it — that claim is examined below, and it does not hold up.

What the evidence actually shows

The human evidence here is genuinely strong — several large Phase 3 trials published in major medical journals, plus an FDA approval.

Weight management (no diabetes) — ATTAIN-1. This Phase 3 trial (NCT05869903, NEJM 2025) ran 72 weeks in adults with obesity. At the highest dose, average weight loss reached up to roughly 12.4% on the efficacy estimand (a way of measuring results as if everyone stayed on the drug as planned) — about 11% on the treatment-regimen estimand (a measure that counts real-world stops and changes) — versus about 2.1% on placebo (a dummy pill), with lower doses landing in between. Most participants on the higher doses lost at least 10% of their weight. The trial enrolled roughly 3,000+ participants across several countries.

Weight plus type 2 diabetes — ATTAIN-2. This Phase 3 trial (NCT05872620, The Lancet, November 2025) followed adults who had both obesity and type 2 diabetes for 72 weeks. The highest dose produced up to roughly 10.5% weight loss, along with an A1C reduction of roughly 1.8% (A1C is a blood test reflecting average blood sugar over about three months).

Phase 2 (obesity). The earlier NEJM 2023 trial showed up to roughly 14.7% average weight loss at 36 weeks — the first strong signal that the later Phase 3 trials went on to confirm.

Maintenance — ATTAIN-MAINTAIN. A Phase 3b trial (NCT06584916, Nature Medicine) tested whether orforglipron could help people hold onto weight loss after coming off an injectable incretin drug. It hit both its main goal and its key secondary goal.

Diabetes program — ACHIEVE. The ACHIEVE-3 head-to-head trial (The Lancet, February 2026) found the 36 mg dose beat oral semaglutide on both A1C (−2.2% vs −1.4%) and weight. Other ACHIEVE trials met their goals according to Lilly’s early summary results.

Muscle. There is no credible orforglipron-specific data showing it protects muscle or lean mass. It is a metabolic and weight-loss drug, not a muscle drug — any “muscle” claim is unsupported.

Preclinical. The work mapping the receptor’s shape and that biased signaling is preclinical pharmacology (lab and animal research done before human trials). Worth noting: orforglipron did not act on the GLP-1 receptor in the rodent species tested and did not cause tumors in rodents — which is relevant to the cautionary thyroid warning covered below.

Legal and regulatory status

Orforglipron is FDA-approved (April 1, 2026) as Foundayo for long-term weight management — for adults with obesity, or who are overweight with at least one weight-related health condition, used alongside a reduced-calorie diet and more physical activity. It is the first oral small-molecule GLP-1 receptor agonist to be approved, and the first GLP-1 pill with no food, water, or time-of-day restrictions. The approval came through the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot — a fast-track program — on a notably quick timeline. It was the first brand-new drug molecule approved under that program.

Type 2 diabetes is not yet approved as of June 2026. The Phase 3 ACHIEVE program backs a diabetes use, and a regulatory filing was expected in 2026, but approval has not happened. It should not be described as approved for diabetes.

Anti-doping. Orforglipron is a GLP-1 receptor agonist, and that class is not on the WADA 2026 Prohibited List (WADA is the World Anti-Doping Agency) — it is not banned in or out of competition. GLP-1 receptor agonists are instead on WADA’s 2026 Monitoring Program, which means they are simply being watched, with no penalties; that monitoring data may shape future decisions. A claim going around online that WADA “moved GLP-1 drugs to full S4 prohibition in January 2026” appears to be false — it traces back to a non-authoritative vendor blog and is contradicted by WADA’s own Monitoring Program document and by medical and sports-law sources. The real status is monitored, not banned. (By contrast, growth-factor agents like MGF and IGF-1 variants are banned under WADA Category S2; orforglipron is a small-molecule incretin-pathway drug, not a growth factor, and is not in S2.)

Safety

Orforglipron carries a boxed warning (the FDA’s strongest label warning) for thyroid C-cell tumors, and it should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) — a type of thyroid cancer — or MEN-2 (an inherited condition that raises the risk of certain tumors). This warning is precautionary and applies to the whole drug class: orforglipron did not act on the GLP-1 receptor in the rodent species tested and did not cause tumors in rodents.

The most common side effects are stomach-related and typical of this drug class: nausea, vomiting, diarrhea, constipation, and belching — mostly mild to moderate, tied to dose, and concentrated early on while the dose is being stepped up. In ATTAIN-1, about a third of participants on the higher doses had nausea, and the share of people quitting because of side effects rose with dose to around 10%, versus roughly 3% on placebo (the exact figures for each dose should be read straight from the NEJM paper).

One encouraging point: ATTAIN-1 showed no liver safety signal — which matters because liver-enzyme spikes sank some other oral small-molecule GLP-1 candidates (including a Pfizer program that was shut down). Beyond that, the usual GLP-1 cautions apply: pancreatitis (inflammation of the pancreas), gallbladder problems, worsening diabetic retinopathy (eye damage from diabetes) in people with diabetes, and low blood sugar when combined with insulin or sulfonylureas (older diabetes pills). Long-term data on heart outcomes and how well the effect lasts are still being gathered.

Bottom line

Orforglipron is one of the better-evidenced compounds in this space: a non-peptide, oral, once-daily GLP-1 receptor agonist with several large published Phase 3 trials and a clean FDA approval (Foundayo, April 2026) for long-term weight management. At the top dose, weight loss runs to roughly 12.4% in obesity without diabetes and roughly 10.5% with diabetes. It is not yet approved for type 2 diabetes. It is a small molecule, not a peptide. There is no evidence it protects or builds muscle. Its drug class is monitored — not banned — by WADA, and the “now banned” rumor is unsupported. The main open questions are long-term heart outcomes and how durable the effect is, plus the standard GLP-1 cautions and a precautionary thyroid boxed warning.

Evidence grade: 9/10 · Strong.

Sources

• FDA approves first new molecular entity under National Priority Voucher program
• FDA label — Foundayo (orforglipron), application #220934
• Eli Lilly — FDA approves Foundayo (orforglipron), the only GLP-1 pill
• AJMC — FDA approves Lilly’s oral GLP-1 orforglipron for obesity
• Phase 2 trial — Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (NEJM 2023)
• ATTAIN-1 (NEJM 2025; NCT05869903)
• ATTAIN-2 (The Lancet 2025; NCT05872620)
• ATTAIN-MAINTAIN (Nature Medicine)
• ACHIEVE-3 vs oral semaglutide — Lilly readout
• Phase 1a (PMID 37344954)
• Phase 1b in type 2 diabetes (PMID 37264711)
• Comprehensive review (Int J Mol Sci 2026, PMC12898445)
• WADA 2026 Prohibited List now in force
• WADA 2026 Monitoring Program (primary document)
• EMJ — GLP-1 RAs monitored at 2026 Winter Olympics
• Brabners — Weight-loss drugs in sport (sports-law analysis)